drugset / Trial / NCT04999605
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent ovarian cancer.
Timeline
- Start
- 2021-06-24
- Primary completion
- 2022-06-10
- Completion
- 2022-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivonescimab | Monoclonal antibody | — | Other |
| Background | Olaparib | Small molecule | — | — |